Cargando…

Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases

Cholestatic liver diseases encompass a wide spectrum of disorders with different causes, resulting in impaired bile flow and accumulation of bile acids and other potentially hepatotoxic cholephils. The understanding of the molecular mechanisms of bile formation and cholestasis has recently improved...

Descripción completa

Detalles Bibliográficos
Autores principales: Halilbasic, Emina, Baghdasaryan, Anna, Trauner, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Health Sciences Division 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633080/
https://www.ncbi.nlm.nih.gov/pubmed/23540496
http://dx.doi.org/10.1016/j.cld.2012.12.001
_version_ 1782266939533426688
author Halilbasic, Emina
Baghdasaryan, Anna
Trauner, Michael
author_facet Halilbasic, Emina
Baghdasaryan, Anna
Trauner, Michael
author_sort Halilbasic, Emina
collection PubMed
description Cholestatic liver diseases encompass a wide spectrum of disorders with different causes, resulting in impaired bile flow and accumulation of bile acids and other potentially hepatotoxic cholephils. The understanding of the molecular mechanisms of bile formation and cholestasis has recently improved significantly through new insights into nuclear receptor (patho)biology. Nuclear receptors are ligand-activated transcription factors, which act as central players in the regulation of genes responsible for elimination and detoxification of biliary constituents accumulating in cholestasis. They also control other pathophysiologic processes such as inflammation, fibrogenesis, and carcinogenesis involved in the pathogenesis and disease progression of cholestasis liver diseases.
format Online
Article
Text
id pubmed-3633080
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Elsevier Health Sciences Division
record_format MEDLINE/PubMed
spelling pubmed-36330802013-05-01 Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases Halilbasic, Emina Baghdasaryan, Anna Trauner, Michael Clin Liver Dis Article Cholestatic liver diseases encompass a wide spectrum of disorders with different causes, resulting in impaired bile flow and accumulation of bile acids and other potentially hepatotoxic cholephils. The understanding of the molecular mechanisms of bile formation and cholestasis has recently improved significantly through new insights into nuclear receptor (patho)biology. Nuclear receptors are ligand-activated transcription factors, which act as central players in the regulation of genes responsible for elimination and detoxification of biliary constituents accumulating in cholestasis. They also control other pathophysiologic processes such as inflammation, fibrogenesis, and carcinogenesis involved in the pathogenesis and disease progression of cholestasis liver diseases. Elsevier Health Sciences Division 2013-05 /pmc/articles/PMC3633080/ /pubmed/23540496 http://dx.doi.org/10.1016/j.cld.2012.12.001 Text en © 2013 Elsevier Inc. https://creativecommons.org/licenses/by/4.0/ Open Access under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) license
spellingShingle Article
Halilbasic, Emina
Baghdasaryan, Anna
Trauner, Michael
Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title_full Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title_fullStr Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title_full_unstemmed Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title_short Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases
title_sort nuclear receptors as drug targets in cholestatic liver diseases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633080/
https://www.ncbi.nlm.nih.gov/pubmed/23540496
http://dx.doi.org/10.1016/j.cld.2012.12.001
work_keys_str_mv AT halilbasicemina nuclearreceptorsasdrugtargetsincholestaticliverdiseases
AT baghdasaryananna nuclearreceptorsasdrugtargetsincholestaticliverdiseases
AT traunermichael nuclearreceptorsasdrugtargetsincholestaticliverdiseases